Flexion Therapeutics discovers and develops innovative therapeutics for musculoskeletal disorders. The company aims to provide products with superior efficacy and safety, by merging novel pharmacology with local, sustained delivery of drug to the site of disease in order to ensure lasting therapeutic effects and systemic safety. The company’s first products represent new medicines in the treatment of osteoarthritis, a leading cause of disability that affects more than 27 million adults in the U.S. and more than 100 million people worldwide. Flexion is advancing a portfolio of best-in-class drug candidates that have the potential to treat mild, moderate and severe forms of this debilitating disorder.

Biopharmaceuticals